These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 16048163)

  • 1. An overview of the drug development process.
    Tonkens R
    Physician Exec; 2005; 31(3):48-52. PubMed ID: 16048163
    [No Abstract]   [Full Text] [Related]  

  • 2. The special treatment.
    Osborne R
    Nat Biotechnol; 2008 May; 26(5):487-9. PubMed ID: 18464770
    [No Abstract]   [Full Text] [Related]  

  • 3. Trials and error.
    Jacobs T
    Nat Biotechnol; 2005 Dec; 23(12):1481. PubMed ID: 16333284
    [No Abstract]   [Full Text] [Related]  

  • 4. Promoting, improving and accelerating the drug development and approval processes.
    Graul AI
    Drug News Perspect; 2009; 22(1):30-8. PubMed ID: 19209297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug evaluation and approval process in the European Union.
    San Miguel MT; Vargas E
    Arthritis Rheum; 2006 Feb; 55(1):12-4. PubMed ID: 16463405
    [No Abstract]   [Full Text] [Related]  

  • 6. Steve Carney talks to Vincent Lee on the pharma industry, the FDA and public education with respect to drugs and their development.
    Lee VH
    Drug Discov Today; 2005 Nov; 10(21):1411-4. PubMed ID: 16243258
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug and vaccine development for infectious diseases: the value of priority review vouchers.
    Matheny J; Smith B; Courtney B; Mair M
    Clin Pharmacol Ther; 2009 Jun; 85(6):571-2. PubMed ID: 19451907
    [No Abstract]   [Full Text] [Related]  

  • 8. Putting pharmacogenetics into practice.
    Hopkins MM; Ibarreta D; Gaisser S; Enzing CM; Ryan J; Martin PA; Lewis G; Detmar S; van den Akker-van Marle ME; Hedgecoe AM; Nightingale P; Dreiling M; Hartig KJ; Vullings W; Forde T
    Nat Biotechnol; 2006 Apr; 24(4):403-10. PubMed ID: 16601719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The identification of benefit in medical intervention: an overview and suggestions for process.
    Stang PE; Pham SV; Kinchen K; Raff SB; Mussen F; Gondek K
    Am J Ther; 2008; 15(5):495-503. PubMed ID: 18806527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Priority review vouchers: an inefficient and dangerous way to promote neglected-disease drug development.
    Kesselheim AS
    Clin Pharmacol Ther; 2009 Jun; 85(6):573-5. PubMed ID: 19451908
    [No Abstract]   [Full Text] [Related]  

  • 11. Drive for drugs leads to baby clinical trials.
    Nature; 2006 Mar; 440(7083):406-7. PubMed ID: 16554774
    [No Abstract]   [Full Text] [Related]  

  • 12. The ODAC Chronicles: part 6b. ODAC's structure and function.
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2005 Oct; 5(5):753-6. PubMed ID: 16221044
    [No Abstract]   [Full Text] [Related]  

  • 13. Working together to enhance the efficiency of medical product development.
    Sanhai WR
    J Nucl Med; 2008 Jun; 49(6):43N-45N. PubMed ID: 18511823
    [No Abstract]   [Full Text] [Related]  

  • 14. How are drugs approved? Part 3. The stages of drug development.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2008 Mar; 46(3):17-20. PubMed ID: 18416270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulators scramble to tighten loopholes after heparin debacle.
    Jia H
    Nat Biotechnol; 2008 May; 26(5):477-8. PubMed ID: 18464756
    [No Abstract]   [Full Text] [Related]  

  • 16. Abbreviated approval process in the works for 'biosimilar' drugs.
    Sipkoff M
    Manag Care; 2007 Apr; 16(4):52, 55. PubMed ID: 17491291
    [No Abstract]   [Full Text] [Related]  

  • 17. The unfinished business of U.S. drug safety regulation.
    Evans BJ; Flockhart DA
    Food Drug Law J; 2006; 61(1):45-63. PubMed ID: 16838457
    [No Abstract]   [Full Text] [Related]  

  • 18. [Europe for the development of pediatric drugs].
    Combes G
    Soins Pediatr Pueric; 2002 Jun; (206):5-6. PubMed ID: 12140944
    [No Abstract]   [Full Text] [Related]  

  • 19. Paving the critical path: how can clinical pharmacology help achieve the vision?
    Lesko LJ
    Clin Pharmacol Ther; 2007 Feb; 81(2):170-7. PubMed ID: 17259944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The risk we bear: the effects of review speed and industry user fees on new drug safety.
    Olson MK
    J Health Econ; 2008 Mar; 27(2):175-200. PubMed ID: 18207263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.